Experiences and preferences about information on treatment-related side effects among patients with early breast cancer

IF 5.7 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Breast Pub Date : 2025-02-06 DOI:10.1016/j.breast.2025.104414

Antonio Di Meglio , Giuseppe Catanuto , Marzia Zambon , Alexandre Chan , Angelos P. Kassianos , Constantina Cloconi , Silvia Rohr , Rebecca Steele , Monique Coersmeyer , Sonia Ujupan , Fedro Peccatori

{"title":"Experiences and preferences about information on treatment-related side effects among patients with early breast cancer","authors":"Antonio Di Meglio , Giuseppe Catanuto , Marzia Zambon , Alexandre Chan , Angelos P. Kassianos , Constantina Cloconi , Silvia Rohr , Rebecca Steele , Monique Coersmeyer , Sonia Ujupan , Fedro Peccatori","doi":"10.1016/j.breast.2025.104414","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Treatment-related side effects are common among women treated for early breast cancer and their effective management is essential to maintain quality of life, ensure treatment adherence, and optimise survival outcomes. This study aimed to investigate patient-reported experiences and preferences about information regarding side effects received during breast cancer care.</div></div><div><h3>Methods</h3><div>An international multi-stakeholder expert group conducted an online patient survey assessing comprehensiveness, timing, and delivery modality of information regarding treatment-related side effects among patients undergoing primary therapy (surgery, radiation, and [neo]adjuvant chemotherapy) and endocrine therapy for early breast cancer. Descriptive analyses were performed.</div></div><div><h3>Results</h3><div>From June–August 2023, 608 respondents from Brazil, France, Germany, Italy, Japan, and Spain completed the survey: 57.5 % were <50 years old, and all were or had been on endocrine therapy. Fatigue was the most reported side effect (47.0 % for primary and 42.3 % for endocrine therapy). A variable proportion of patients (14.4%–46.8 % across side effects) reported receiving information only after having experienced the side effect. Up to 43.6 % of respondents reported receiving insufficient or no information on side effects from their healthcare providers. Most patients reported preference for proactive communication from healthcare providers about side effects and prevention strategies. Respondents valued direct interactions with physicians and nurses and capitalised on a relevant role for peer-support, however utility of smartphone and web-based platforms to record and manage symptoms was acknowledged.</div></div><div><h3>Conclusion</h3><div>The survey underscores critical needs and offers insight informing the provision of comprehensive and timely information on treatment-related side effects across the cancer survivorship continuum.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"80 ","pages":"Article 104414"},"PeriodicalIF":5.7000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960977625000335","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Treatment-related side effects are common among women treated for early breast cancer and their effective management is essential to maintain quality of life, ensure treatment adherence, and optimise survival outcomes. This study aimed to investigate patient-reported experiences and preferences about information regarding side effects received during breast cancer care.

Methods

An international multi-stakeholder expert group conducted an online patient survey assessing comprehensiveness, timing, and delivery modality of information regarding treatment-related side effects among patients undergoing primary therapy (surgery, radiation, and [neo]adjuvant chemotherapy) and endocrine therapy for early breast cancer. Descriptive analyses were performed.

Results

From June–August 2023, 608 respondents from Brazil, France, Germany, Italy, Japan, and Spain completed the survey: 57.5 % were <50 years old, and all were or had been on endocrine therapy. Fatigue was the most reported side effect (47.0 % for primary and 42.3 % for endocrine therapy). A variable proportion of patients (14.4%–46.8 % across side effects) reported receiving information only after having experienced the side effect. Up to 43.6 % of respondents reported receiving insufficient or no information on side effects from their healthcare providers. Most patients reported preference for proactive communication from healthcare providers about side effects and prevention strategies. Respondents valued direct interactions with physicians and nurses and capitalised on a relevant role for peer-support, however utility of smartphone and web-based platforms to record and manage symptoms was acknowledged.

Conclusion

The survey underscores critical needs and offers insight informing the provision of comprehensive and timely information on treatment-related side effects across the cancer survivorship continuum.

查看原文本刊更多论文

早期乳腺癌患者治疗相关副作用信息的经验和偏好

背景：治疗相关的副作用在早期乳腺癌治疗的女性中很常见，对其进行有效管理对于维持生活质量、确保治疗依从性和优化生存结果至关重要。本研究旨在调查患者报告的经历和对乳腺癌治疗期间收到的副作用信息的偏好。方法一个国际多方利益相关者专家组进行了一项在线患者调查，评估早期乳腺癌患者接受主要治疗（手术、放疗和[neo]辅助化疗）和内分泌治疗时治疗相关副作用信息的综合性、时机和传递方式。进行描述性分析。结果2023年6 - 8月，来自巴西、法国、德国、意大利、日本和西班牙的608名受访者完成了调查，其中57.5%的受访者年龄为50岁，全部正在或曾经接受内分泌治疗。疲劳是报告最多的副作用（原发性治疗为47.0%，内分泌治疗为42.3%）。不同比例的患者（14.4% - 46.8%的副作用）报告在经历副作用后才接受信息。多达43.6%的受访者报告说，他们从医疗保健提供者那里获得的关于副作用的信息不足或根本没有。大多数患者报告倾向于与医疗保健提供者就副作用和预防策略进行主动沟通。受访者重视与医生和护士的直接互动，并充分发挥同伴支持的相关作用，但也承认使用智能手机和基于网络的平台来记录和管理症状。结论：该调查强调了关键的需求，并提供了关于癌症生存连续体中治疗相关副作用的全面和及时的信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast 医学-妇产科学

CiteScore

8.70

自引率

2.60%

发文量

165

审稿时长

59 days

期刊介绍： The Breast is an international, multidisciplinary journal for researchers and clinicians, which focuses on translational and clinical research for the advancement of breast cancer prevention, diagnosis and treatment of all stages.